Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 5/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.46 |
| ▸ | MMP9 | P14780 | 9/20 | 0.46 |
| ▸ | MMP13 | P45452 | 7/20 | 0.46 |
| ▸ | MMP1 | P03956 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7257038 | 0.93 | KEAP1 (0.48) | KEAP1NFE2L2MMP9MMP13MMP1 | |
| SCHEMBL7455279 | 0.83 | TEAD1 (0.43) | KEAP1NFE2L2LMNAMAPT | |
| SCHEMBL2579843 | 0.82 | RORC (0.43) | KEAP1NFE2L2NR3C1PGRTAS2R14 | |
| SCHEMBL2577766 | 0.82 | MCL1 (0.44) | KEAP1NFE2L2NR3C1TAS2R14MAPT | |
| SCHEMBL7255192 | 0.82 | ACHE (0.43) | NR3C1MAPT | |
| SCHEMBL2581868 | 0.81 | TAS2R14 (0.43) | KEAP1NFE2L2MMP9MMP13MMP1 | |
| SCHEMBL7252238 | 0.80 | MAPT (0.52) | KEAP1NFE2L2LMNANR3C1ALDH1A1 | |
| SCHEMBL5996194 | 0.77 | CYP2C8 (0.40) | KEAP1NFE2L2LMNA | |
| SCHEMBL2581362 | 0.76 | KEAP1 (0.47) | KEAP1NFE2L2 | |
| SCHEMBL5981554 | 0.76 | MCL1 (0.39) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43802-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-11-13 | — | — | US | claimed |
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-10-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | KEAP1 4367/4885NFE2L2 3961/4885MMP9 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.